Patient P-01709
Therapy response
Declining
Tolerance
Improving
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Declining
Discontinuation risk
64%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 58 ME-01 recommended — Monitoring Escalation ME-01
- Day 59 GI-04 recommended — GI Support Protocol GI-04
- Day 59 Patient accepted — Started ME-01 in the companion
- Day 60 Patient accepted — Started GI-04 in the companion
- Day 62 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 68 GI symptom burden −19% vs expected — GI Support Protocol GI-04
- Day 74 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 44.
Primary contributors, last 14 days
- Nutritional resilience-7
- Inflammatory activity-6
- Toxicity-6
- Treatment adherence+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- Monitoring Escalation ME-01Day 58Result: deterioration detected before clinical escalation
- GI Support Protocol GI-04Day 59Result: symptom burden −19%
LIFE OS recommendation
Clinician Review CR-01
82%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 47
- WearableHRV 28 ms, trending down
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 36/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 77 bpm
- Wearable1,486 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.5 · butyrate capacity 36/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 25 ms
- Sleep
- 7.1 h
- Steps
- 1,950
- Resting HR
- 78 bpm
Daily log: GI score 53, nutritional resilience 43, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01330 | 63% | S14 | GI-04 | improved | 47 |
| P-01409 | 57% | S14 | SC-12 | improved | 41 |
| P-01431 | 53% | S14 | GI-04 | improved | 41 |
| P-01556 | 53% | S14 | GI-04 | improved | 44 |
| P-01429 | 52% | S09 | GI-04 | improved | 45 |
| P-01692 | 52% | S14 | NP-02 | improved | 49 |
| P-01433 | 51% | S14 | GI-04 | improved | 48 |
| P-01570 | 51% | S14 | SC-12 | improved | 46 |
| P-01661 | 51% | S03 | GI-04 | improved | 52 |
| P-01834 | 51% | S14 | NP-02 | improved | 44 |
| P-01872 | 51% | S14 | NP-02 | improved | 47 |
| P-01406 | 50% | S18 | GI-04 | improved | 50 |